# Symptoms and stages of anaplastic thyroid carcinoma
Anaplastic thyroid carcinoma (ATC) is a highly aggressive form of thyroid cancer that clinically distinguishes itself from other thyroid cancer types. This tab describes how the disease manifests in the body and how it develops over time.
Early phase: initial symptoms and diagnosis
In the early stage, many patients notice rapid swelling at the front of the neck, usually on one side. This swelling grows noticeably over days to weeks and feels hard. The skin on it may appear red or tense and feel warm.
Common symptoms during this period are:
- **Neck complaints**: difficulty swallowing (dysphagia), often mainly for solid foods, and sometimes pain when swallowing
- **Voice and breathing problems**: hoarseness or change in voice, sometimes coughing fits
- **Neck and throat pain**: usually one-sided, can radiate to ear, jaw or shoulder
- **Swelling of lymph nodes**: palpable lumps on the side of the neck
- **Mild general malaise**: fatigue, possibly slight fever
These symptoms arise because the tumor rapidly increases in size and presses on the trachea, esophagus and nerves. In this phase, the patient often visits a general practitioner or ear, nose and throat specialist, followed by examinations (ultrasound, CT scan, biopsy).
Diagnosis usually occurs via needle biopsy (fine-needle aspiration cytology) or tissue biopsy, whereby the pathologist determines under the microscope that these are anaplastic cells. This can become clear within several days to two weeks.
**What it means for daily life:**
Patients may notice that they have difficulty eating and drinking, possibly develop preferences for soft foods and warmth. Speech may change, which can be socially noticeable. The uncertainty and anxiety surrounding the rapid diagnosis can be significant.
---
Locally advanced stage (locally advanced disease)
Once diagnosed, most patients find that the tumor has already grown deeply into surrounding tissues. This locally advanced stage is determined via CT or MRI scan.
Symptoms that may worsen or reappear:
- **More severe breathing problems**: becoming short of breath more quickly, wheezing or rasping breathing, possible feeling of suffocation
- **Feeding problem**: more difficulty with everything you eat, possible withdrawal to only liquids or purées
- **Pain**: especially with neck movement, sometimes radiating to shoulder or arm (due to nerve involvement)
- **Facial and facial edema**: swelling of face or lips as lymphatic vessels become obstructed
- **Cough and discolored sputum**: as the tumor sits closer against the trachea
- **Night sweats and loss of sensation**: appear as nerves become affected
By this point, the tumor may be in contact with the trachea, esophagus, blood vessels or nerves, sometimes adhering to them. This largely determines what type of treatment is possible.
**What it means for daily life:**
Breathing may noticeably become labored, especially during physical exertion or when lying down. Many patients use multiple pillows and sleep upright. Eating becomes increasingly a careful activity; weight loss is not unusual. Fear of sudden breathing problems can increase significantly, especially at night.
**Numbers about this stage:**
In anaplastic thyroid carcinoma, one usually speaks of an advanced stage immediately (TNM stage IVA, IVB or IVC). Approximately 80–90% of patients already have local invasion or metastases elsewhere at diagnosis. A precise subdivision into "early" and "late" stages is more difficult domestically because the disease is by definition aggressive. The median survival for the entire ATC cohort (all stages) is around 5–12 months (source: various population-based analyses, 2023–2025); patients with locally advanced disease without metastases have better survival rates in some studies (up to approximately 20–24 months with combination treatment), but there is also great individual variation here. These figures are averages across large groups and say nothing about the prognosis of one person — this depends heavily on factors such as age, overall health, genetic mutations and whether treatment can take place.
---
Stage with metastases (metastatic)
In approximately 40–50% of ATC patients, metastases are already detected at the time of diagnosis. These are usually located in:
- **Lung** (most frequent, up to 70% of metastatic cases)
- **Bones** (up to 30–40%)
- **Brain** (10–20%)
- **Liver** (5–15%)
- **Peritoneum** (less frequent)
Symptoms may be related to where the metastases are located and how large they are:
**With lung metastases:**
- Shortness of breath, especially during exertion
- Cough, possibly with bloody sputum
- Chest pain on deep breathing
- Generalized fatigue
**With brain metastases:**
- Headache (often persistent, sometimes worse in the morning)
- Dizziness or balance disorders
- Confusion, memory problems or concentration problems
- Visual disturbances (impaired vision, double vision)
- Sometimes seizures
**With bone metastases:**
- Bone pain, especially in the spine, pelvis, ribs or femur
- Tenderness or swelling at the site
- Weakness of limbs if the spine is affected
**General symptoms of metastatic disease:**
- Weight loss (often considerable and rapid)
- Fatigue that does not improve with rest
- Night sweats
- Reduced appetite
- Palpable lymph nodes in multiple locations (armpit, groin, neck)
**What it means for daily life:**
Patients usually report severely reduced energy reserves; many activities feel impossible. Eating and personal hygiene become strenuous. Fear of new symptoms increases. Home situation changes: help needed with everyday things, possible hospital visits become more frequent. Intra-family dynamics shift.
**Numbers about this stage:**
The median survival for patients with metastatic ATC without treatment is 3–6 months (source: various observational studies from 2020–2024). With modern multimodal treatment (surgery where feasible, radiotherapy, chemotherapy and/or targeted therapy), some centres can report slightly better outcomes, with median survival of 10–15 months in selected cohorts, but this varies greatly by centre and patient factors. All figures are population averages; individual patients may survive shorter or longer depending on how well their body responds to treatment, their overall fitness and other disease speed determinants. The first moment when metastases are diagnosed is crucial for staging: some patients notice symptoms of metastases earlier than others.
---
Refractory stage (treatment resistance)
As treatment progresses, tumours can become "resistant" to chemotherapy or targeted drugs. This happens when tumour cells make genetic changes that make them susceptible to a different type of drug or no longer responsive to treatment at all.
Symptoms in this phase overlap with those described earlier, but:
- **Accelerated return of symptoms** after periods of response: swelling grows again faster, breathing deteriorates again
- **New symptoms from metastases**: e.g., sudden nerve pain as a brain metastasis grows
- **Side effects persist**, while treatment becomes less effective (fatigue, nausea, loss of appetite may worsen without the tumor shrinking)
- **Noticeable decline**: faster aging, weight loss accelerates, strength continues to decrease
In this phase, treatment texts may refer to "refractory" or "resistant" disease, meaning standard chemotherapy or earlier targeted drugs no longer help.
**What it means for daily life:**
Many patients feel stuck: they undergo treatment, experience side effects, but don't see the tumor shrink or recede. Emotionally this can be very distressing. Many conversations with the doctor focus on "what now?" — switching to a different drug, clinical trial, supportive care.
**Numbers about this stage:**
For refractory ATC, median survival without effective second-line treatment is approximately 2–4 months (source: observational studies, 2022–2025). Certain targeted therapies (for example, BRAF inhibitors for BRAF V600E-mutated tumours, ALK or RET inhibitors where relevant, or immunotherapy) can provide survival benefit in subgroups, but this is highly variable by mutation type. For patients without actionable mutations, the prognosis may be even more limited. Here too there are major individual differences, and response to new drugs is not predictable without trying them.
---
Final phase (palliative/end of life)
In the final weeks to days of life, symptoms can intensify greatly:
- **Severe breathing difficulties**: possible rattling of mucus, shallow or irregular breathing
- **Confusion or unconsciousness**: caused by the tumour's effect on the brain, metabolic disturbances, or medications
- **Uncontrolled pain**: without adequate pain relief
- **Inability to take fluids**: swallowing no longer works
- **Restlessness or anxiety**: despite medication
- **Bleeding**: rare, but possible from the mouth and throat
The transition from active treatment to palliative care (focused on comfort rather than cure) usually happens when further chemotherapy offers no benefit and body functions decline more rapidly. This moment differs per patient.
**What it means for daily life:**
In this phase, the patient is usually at home (or in hospice) and comfort is central. Family and regular people from the patient's circle are present. Pain and anxiety management, mouth and body care, and emotional support form the core of care.
---
When to contact your healthcare provider?
It is important to make contact when:
- **Sudden worsening of breathing**: breathlessness that increases rapidly or feels like suffocation — this can be an emergency
- **Severe uncontrolled pain**: despite prescribed pain medication
- **Neurological symptoms**: sudden confusion, speech problems, weakness in arms or legs (suggesting brain metastases or other complication)
- **High fever or signs of infection**: chills, severe malaise
- **Uncontrolled nausea or vomiting**: preventing you from drinking or taking medication
- **Injuries or bleeding**: especially if blood appears in the mouth or sputum
- **Severe side effects of treatment**: that severely limit your daily life
Also for questions about symptom management, treatment choices, or transitions to other care, it is advisable to contact the treatment team. They can alert facilities or emergency services.